FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2155244795> ?p ?o ?g. }

• W2155244795 endingPage "389" @default.
• W2155244795 startingPage "381" @default.
• W2155244795 abstract "Neuropilin-2, a cell surface receptor involved in angiogenesis and axonal guidance, has recently been shown to be a critical mediator of tumor-associated lymphangiogenesis. Given that lymphangiogenesis is a major conduit of metastasis in melanomas and that blocking neuropilin-2 function in vivo is effective in inhibiting tumor cell metastasis, we sought to determine the clinical relevance of neuropilin-2 expression in cutaneous melanoma. Immunohistochemical analysis of neuropilin-2 expression was evaluated in nevomelanocytic proliferations that included a tissue microarray and histologic sections from samples of primary melanomas (n = 42; 40 for tissue microarray, 2 for histologic sections), metastatic melanomas (n = 30; 22 for tissue microarray, 8 for histologic sections), and nevi (n = 30; 5 for tissue microarray, 25 for histologic sections), as well as a panel of normal human tissues and select nonmelanocytic tumors. Staining for grading and intensity of neuropilin-2 expression was estimated semiquantitatively as follows for the former: less than 20%, 20% to 60%, and more than 60% of tissue present, and for the latter from 0 to 3, with 3 being the highest and 0 the lowest intensity. In nevomelanocytic proliferations, more than 20% staining for neuropilin-2 was noted in 36 (86%) of 42 cases of primary melanoma, in 27 (90%) of 30 cases of metastatic melanoma, and in 9 (30%) of 30 cases of nevi with differences achieving statistical significance between melanoma (primary and metastatic) and nevi (P < .0001). For staining intensity, an intensity of 2 or more was noted in 36 (86%) of 42 cases of primary melanoma, in 17 (57%) of 30 cases of metastatic melanoma and in 7 (30%) of 23 cases of nevi, with differences achieving statistical significance between melanoma (primary and metastatic) and nevi (P < .0001). In normal human tissue, consistently strong neuropilin-2 staining was noted in kidney (glomerular endothelial cells, collecting tubules, and collecting ducts), skin (epidermal keratinocytes), and testes (epithelium of the seminiferous tubules), whereas in tumoral tissue, consistently strong staining was noted only in renal cell carcinoma but not in any of the other tumors studied. More recently, using a heterotypic coculture methodology with melanoma and endothelial cells, we have demonstrated successful up-regulation of neuropilin-2 and confirmed the critical role of neuropilin-2 in melanoma-endothelial interactions. Because these coculture methods were developed to model melanoma metastasis, the significantly increased and enhanced expression of neuropilin-2 staining in primary and metastatic melanoma versus nevi in the current study suggests that it is also relevant in vivo." @default.
• W2155244795 created "2016-06-24" @default.
• W2155244795 creator A5009105564 @default.
• W2155244795 creator A5021281217 @default.
• W2155244795 creator A5023901900 @default.
• W2155244795 creator A5027415725 @default.
• W2155244795 creator A5042213067 @default.
• W2155244795 creator A5049042102 @default.
• W2155244795 creator A5055449927 @default.
• W2155244795 creator A5062308593 @default.
• W2155244795 creator A5079631407 @default.
• W2155244795 creator A5085943728 @default.
• W2155244795 creator A5089353809 @default.
• W2155244795 creator A5089551599 @default.
• W2155244795 date "2012-03-01" @default.
• W2155244795 modified "2023-10-07" @default.
• W2155244795 title "Neuropilin-2: a novel biomarker for malignant melanoma?" @default.
• W2155244795 cites W1558361583 @default.
• W2155244795 cites W1988024355 @default.
• W2155244795 cites W1995280612 @default.
• W2155244795 cites W1997307365 @default.
• W2155244795 cites W1999738231 @default.
• W2155244795 cites W2003742281 @default.
• W2155244795 cites W2010679818 @default.
• W2155244795 cites W2014608793 @default.
• W2155244795 cites W2023275023 @default.
• W2155244795 cites W2032910847 @default.
• W2155244795 cites W2042855108 @default.
• W2155244795 cites W2047096720 @default.
• W2155244795 cites W2048927019 @default.
• W2155244795 cites W2050904301 @default.
• W2155244795 cites W2059778390 @default.
• W2155244795 cites W2074110731 @default.
• W2155244795 cites W2086530521 @default.
• W2155244795 cites W2088252322 @default.
• W2155244795 cites W2095156039 @default.
• W2155244795 cites W2096643761 @default.
• W2155244795 cites W2101703760 @default.
• W2155244795 cites W2111818745 @default.
• W2155244795 cites W2124832817 @default.
• W2155244795 cites W2136927379 @default.
• W2155244795 cites W2147153812 @default.
• W2155244795 cites W2153766534 @default.
• W2155244795 cites W2168616374 @default.
• W2155244795 cites W2395003662 @default.
• W2155244795 cites W2472034163 @default.
• W2155244795 cites W71022479 @default.
• W2155244795 doi "https://doi.org/10.1016/j.humpath.2011.05.008" @default.
• W2155244795 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3246122" @default.
• W2155244795 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21840568" @default.
• W2155244795 hasPublicationYear "2012" @default.
• W2155244795 type Work @default.
• W2155244795 sameAs 2155244795 @default.
• W2155244795 citedByCount "23" @default.
• W2155244795 countsByYear W21552447952013 @default.
• W2155244795 countsByYear W21552447952014 @default.
• W2155244795 countsByYear W21552447952016 @default.
• W2155244795 countsByYear W21552447952017 @default.
• W2155244795 countsByYear W21552447952018 @default.
• W2155244795 countsByYear W21552447952019 @default.
• W2155244795 countsByYear W21552447952020 @default.
• W2155244795 countsByYear W21552447952021 @default.
• W2155244795 countsByYear W21552447952022 @default.
• W2155244795 countsByYear W21552447952023 @default.
• W2155244795 crossrefType "journal-article" @default.
• W2155244795 hasAuthorship W2155244795A5009105564 @default.
• W2155244795 hasAuthorship W2155244795A5021281217 @default.
• W2155244795 hasAuthorship W2155244795A5023901900 @default.
• W2155244795 hasAuthorship W2155244795A5027415725 @default.
• W2155244795 hasAuthorship W2155244795A5042213067 @default.
• W2155244795 hasAuthorship W2155244795A5049042102 @default.
• W2155244795 hasAuthorship W2155244795A5055449927 @default.
• W2155244795 hasAuthorship W2155244795A5062308593 @default.
• W2155244795 hasAuthorship W2155244795A5079631407 @default.
• W2155244795 hasAuthorship W2155244795A5085943728 @default.
• W2155244795 hasAuthorship W2155244795A5089353809 @default.
• W2155244795 hasAuthorship W2155244795A5089551599 @default.
• W2155244795 hasBestOaLocation W21552447952 @default.
• W2155244795 hasConcept C121608353 @default.
• W2155244795 hasConcept C126322002 @default.
• W2155244795 hasConcept C142724271 @default.
• W2155244795 hasConcept C18903297 @default.
• W2155244795 hasConcept C193270364 @default.
• W2155244795 hasConcept C204232928 @default.
• W2155244795 hasConcept C2776636583 @default.
• W2155244795 hasConcept C2777286243 @default.
• W2155244795 hasConcept C2777658100 @default.
• W2155244795 hasConcept C2779013556 @default.
• W2155244795 hasConcept C502942594 @default.
• W2155244795 hasConcept C71924100 @default.
• W2155244795 hasConcept C86803240 @default.
• W2155244795 hasConceptScore W2155244795C121608353 @default.
• W2155244795 hasConceptScore W2155244795C126322002 @default.
• W2155244795 hasConceptScore W2155244795C142724271 @default.
• W2155244795 hasConceptScore W2155244795C18903297 @default.
• W2155244795 hasConceptScore W2155244795C193270364 @default.
• W2155244795 hasConceptScore W2155244795C204232928 @default.
• W2155244795 hasConceptScore W2155244795C2776636583 @default.

• next